XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20

(2020) Xu-Wen Guan et al.   Cell Death & Disease

MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer

(2020) Arnaud Augert et al.   CANCER CELL

MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate

(2020) Abbie S. Ireland et al.   CANCER CELL

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

(2020) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Next-generation characterization of the Cancer Cell Line Encyclopedia

(2019) Mahmoud Ghandi et al.   NATURE

Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer

(2019) Priyanka Chowdhury et al.   BMC CANCER

Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer

(2019) Sunwang Xu et al.   Nature Communications

The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer

(2018) Alice Lallo et al.   CLINICAL CANCER RESEARCH

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

(2018) M. Catherine Pietanza et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas

(2018) Natalia Saenz-Ponce et al.   Science Translational Medicine

Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma

(2018) Dan Yue et al.   Cell Death & Disease

A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

(2018) Florence Atrafi et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

(2018) Taofeek K. Owonikoko et al.   JOURNAL OF CLINICAL ONCOLOGY

The PRIDE database and related tools and resources in 2019: improving support for quantification data

(2018) Yasset Perez-Riverol et al.   NUCLEIC ACIDS RESEARCH

Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations

(2017) Tadaaki Yamada et al.   MOLECULAR CANCER THERAPEUTICS

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

(2017) Johann de Bono et al.   Cancer Discovery

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II  to the Nucleus

(2016) P. Ranganathan et al.   CLINICAL CANCER RESEARCH

PARP inhibitor combination therapy

(2016) Amy Dréan et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

(2016) Joel G. Turner et al.   Journal of Hematology & Oncology

AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers

(2016) Kavitha Balaji et al.   MOLECULAR CANCER RESEARCH

Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer

(2016) Robert J. Cardnell et al.   PLoS One

Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling

(2015) F. Conforti et al.   CLINICAL CANCER RESEARCH

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy

(2013) K. Yuan et al.   CLINICAL CANCER RESEARCH

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

(2013) R. J. Cardnell et al.   CLINICAL CANCER RESEARCH

Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

(2013) J. E. Allen et al.   Science Translational Medicine

Beyond DNA Repair: Additional Functions of PARP-1 in Cancer

(2013) Alice N. Weaver et al.   Frontiers in Oncology

Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia

(2012) Francesca Buontempo et al.   CELL CYCLE

NESdb: a database of NES-containing CRM1 cargoes

(2012) Darui Xu et al.   MOLECULAR BIOLOGY OF THE CELL

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

(2012) Lauren Averett Byers et al.   Cancer Discovery

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

(2012) Yasir H. Ibrahim et al.   Cancer Discovery

Nuclear export of proteins and drug resistance in cancer

(2011) Joel G. Turner et al.   BIOCHEMICAL PHARMACOLOGY

The Complex Biology of FOXO

(2011) Maria Monsalve et al.   CURRENT DRUG TARGETS

I B kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia

(2010) N. Chapuis et al.   BLOOD

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome

(2009) George Poulogiannis et al.   HISTOPATHOLOGY

Structural basis for leucine-rich nuclear export signal recognition by CRM1

(2009) Xiuhua Dong et al.   NATURE

Erratum: Functional interaction between FOXO3a and ATM regulates DNA damage response

(2009) Wen-Bin Tsai et al.   NATURE CELL BIOLOGY

CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer

(2008) Joel Turner et al.   CURRENT MEDICINAL CHEMISTRY

Reorganization of the nuclear envelope during open mitosis

(2008) Ulrike Kutay et al.   CURRENT OPINION IN CELL BIOLOGY